MiR-223 modulates hepatocellular carcinoma cell proliferation through promoting apoptosis via the Rab1-mediated mTOR activation

被引:51
作者
Dong, Zheng [1 ]
Qi, Ruizhao [2 ]
Guo, Xiaodong [3 ]
Zhao, Xin [2 ]
Li, Yinyin [1 ]
Zeng, Zhen [1 ]
Bai, Wenlin [1 ]
Chang, Xiujuan [1 ]
Hao, Liyan [4 ]
Chen, Yan [1 ]
Lou, Min [1 ]
Li, Zhiwei [2 ]
Lu, Yinying [1 ]
机构
[1] 302 Hosp, Comprehens Liver Canc Ctr, Beijing, Peoples R China
[2] 302 Hosp, Dept Gen Surg, Beijing, Peoples R China
[3] 302 Hosp, Dept Pathol, Beijing, Peoples R China
[4] 302 Hosp, Dept Nursing, Beijing, Peoples R China
基金
美国国家科学基金会;
关键词
Rab1; Hepatocellular carcinoma; miR-223; Apoptosis; mTOR; RETICULUM STRESS; CANCER CELLS; BIOMARKERS; PATHWAY; GROWTH; LIVER; INHIBITORS; SORAFENIB; GTPASES; BETA;
D O I
10.1016/j.bbrc.2016.12.091
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Hepatocellular carcinoma (HCC) is a common digestive malignancy. MiR-223, a well-identified miRNA, exhibits diverse properties in different cancers. In this study, we demonstrated that miR-223 could suppress cell growth and promote apoptosis in HepG2 and Bel-7402 HCC cell lines. We screened and identified a novel miR-223 target, Ras-related protein Rab-1(Rab1). Upregulation of miR-223 would specifically and markedly down-regulate Rab1 expression. In addition, miR-223-overexpressing subclones showed significant cell growth inhibition by increasing cell apoptosis in HepG2 and Bel-7402 cells. To identify the mechanisms, we firstly investigated the mTOR pathway and found that pmTOR, p70S6K and Bcl-2 were dramatically down-regulated after miR-223 transfection, while no changes in the level of Bax was visualized. Furthermore, our data showed that the anti-tumor effects arising from miR-223 transfection in HCC cells may be due to the deactivation of mTOR pathway caused by the suppression of Rab1 expression when miR-223 is overexpressed. In summary, our results indicate that miR-223 functions as a tumor suppressor and plays a critical role in inhibiting the tumorigenesis and promoting the apoptosis of HCC through the mTOR signaling pathway in vitro. By targeting Rab1, miR-223 efficiently mediates the mTOR pathway. Given these, miR-223 may be a potential therapeutic target for treating HCC. c 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:630 / 637
页数:8
相关论文
共 35 条
[1]
Making sense of amino acid sensing [J].
Abraham, Robert T. .
SCIENCE, 2015, 347 (6218) :128-129
[2]
[Anonymous], LANCET ONCOL
[3]
Serum miR-30e and miR-223 as Novel Noninvasive Biomarkers for Hepatocellular Carcinoma [J].
Bhattacharya, Sourav ;
Steele, Robert ;
Shrivastava, Shubham ;
Chakraborty, Sounak ;
Di Bisceglie, Adrian M. ;
Ray, Ratna B. .
AMERICAN JOURNAL OF PATHOLOGY, 2016, 186 (02) :242-247
[4]
Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy [J].
Chang, Zhexing ;
Shi, Guang ;
Jin, Jiqiang ;
Guo, Huatao ;
Guo, Xuefeng ;
Luo, Fangyue ;
Song, Yuguo ;
Jia, Xiaojing .
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2013, 31 (06) :1449-1456
[5]
CXC195 induces apoptosis and endoplastic reticulum stress in human hepatocellular carcinoma cells by inhibiting the PI3K/Akt/mTOR signaling pathway [J].
Chen, Xiao-Liang ;
Fu, Jian-Ping ;
Shi, Jun ;
Wan, Ping ;
Cao, Hong ;
Tang, Zhi-Mou .
MOLECULAR MEDICINE REPORTS, 2015, 12 (06) :8229-8236
[6]
Challenges of advanced hepatocellular carcinoma [J].
Colagrande, Stefano ;
Inghilesi, Andrea L. ;
Aburas, Sami ;
Taliani, Gian G. ;
Nardi, Cosimo ;
Marra, Fabio .
WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (34) :7645-7659
[8]
Dhanasekaran R., 2013, J CANC THER, V04, P7
[9]
Sulfatide epigenetically regulates miR-223 and promotes the migration of human hepatocellular carcinoma cells [J].
Dong, Yi Wei ;
Wang, Rong ;
Cai, Qian Qian ;
Qi, Bing ;
Wu, Wei ;
Zhang, Yong Hu ;
Wu, Xing Zhong .
JOURNAL OF HEPATOLOGY, 2014, 60 (04) :792-801
[10]
Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway [J].
Fabris, L. ;
Berton, S. ;
Citron, F. ;
D'Andrea, S. ;
Segatto, I. ;
Nicoloso, M. S. ;
Massarut, S. ;
Armenia, J. ;
Zafarana, G. ;
Rossi, S. ;
Ivan, C. ;
Perin, T. ;
Vaidya, J. S. ;
Avanzo, M. ;
Roncadin, M. ;
Schiappacassi, M. ;
Bristow, R. G. ;
Calin, G. ;
Baldassarre, G. ;
Belletti, B. .
ONCOGENE, 2016, 35 (37) :4914-4926